Skip to main content
. Author manuscript; available in PMC: 2020 Jul 10.
Published in final edited form as: ASAIO J. 2015 May-Jun;61(3):244–252. doi: 10.1097/MAT.0000000000000208

Figure 3.

Figure 3.

Comparison of change in intraplatelet ROS levels in controls and before and after implantation with three different kinds of CF-LVADs. (A) Box-whisker plots showing control and baseline values of intraplatelet ROS in patients with different CF-LVAD settings. The lines across each box plot represent the median value. The lines that extend from the top and the bottom of each box represent the lowest and highest observations still inside the lower and upper limit of confidence. *p<0.05 is considered significant in Mann-Whitney U test. (B) Change in post-operative levels of intraplatelet ROS between different devices specific patients during the study period. Data are expressed as mean±SD. *,p<0.05 compared with HeartMate II and †,p<0.05 compared with Jarvik in Student’s t-test. (C) Immunofluorescence microscopy showing DCF-DA positive platelets (green) as an indicator of intraplatelet ROS generation. Note higher fluorescence intensity among HF patient supported by HeartWare in comparison to HeartMate II and Jarvik. Magnification×1000.